Free Trial

AbbVie (ABBV) News Today

AbbVie logo
$228.57 -2.82 (-1.22%)
Closing price 03:59 PM Eastern
Extended Trading
$229.38 +0.81 (+0.35%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Why Is AbbVie Down Today?

AbbVie Inc. (ABBV) — shares are down after a mixed news flow. Positive catalysts (strong drug wins, pipeline progress and M&A) support upside, but near-term selling and analyst EPS cuts are weighing on the stock following a large run-up earlier this year.

  • Positive Sentiment: Key trial result: AbbVie's Rinvoq outperformed Humira in a major arthritis trial — a clinical win that supports continued commercial momentum for its immunology franchise. Article Title
  • Positive Sentiment: Migraine pipeline progress: Positive Phase 3 update for atogepant signals growth beyond core immunology drugs and strengthens long-term revenue diversification. Article Title
  • Positive Sentiment: M&A: AbbVie completed the acquisition of Gilgamesh Pharma (bretilsilocin), expanding its CNS/migraine portfolio and pipeline breadth. Article Title
  • Positive Sentiment: Analyst support: A Cerity Partners commentator highlighted AbbVie’s attractive valuation and dividend yield, which can attract income-focused buyers. Article Title
  • Neutral Sentiment: Momentum note: Zacks and other outlets highlight that ABBV is up >30% in six months driven by Skyrizi/Rinvoq and oncology gains — that explains some recent profit-taking. Article Title
  • Neutral Sentiment: Investor interest: Zacks and MarketBeat pieces note ABBV as a trending/long-term dividend pick, underscoring buy-and-hold narratives even as volatility continues. Article Title
  • Negative Sentiment: Estimate cuts: Zacks Research trimmed Q1 2026 EPS forecasts and flagged a negative near-term outlook, which likely contributed to downward pressure on the share price. Article Title

Takeaway for investors: the stock’s pullback reflects short-term profit-taking and an analyst EPS reduction despite tangible product- and pipeline-driven positives (Rinvoq/Skyrizi momentum, migraine program, M&A). If you hold ABBV, weigh near-term estimate risk against durable cash flow, dividend strength and recent clinical/commercial catalysts.

Posted 16m agoAI Generated. May Contain Errors.

ABBV Latest News

Ethic Inc. Lowers Holdings in AbbVie Inc. $ABBV
Zacks Research Issues Negative Outlook for AbbVie Earnings
Exencial Wealth Advisors LLC Cuts Position in AbbVie Inc. $ABBV
D.A. Davidson & CO. Reduces Stake in AbbVie Inc. $ABBV
AbbVie's Rinvoq Beats Humira in Key Arthritis Trial
AbbVie Inc. $ABBV Shares Sold by Sanders Morris Harris LLC
AbbVie Inc. $ABBV Shares Sold by Beech Hill Advisors Inc.
Whittier Trust Co. Buys 9,073 Shares of AbbVie Inc. $ABBV
AbbVie Inc. $ABBV Shares Acquired by VCI Wealth Management LLC
AbbVie (NYSE:ABBV) Trading Up 1.1% - Here's What Happened
CMG Global Holdings LLC Has $392,000 Stake in AbbVie Inc. $ABBV
AbbVie Inc. $ABBV Shares Sold by Goldstein Advisors LLC
AbbVie Inc. $ABBV Position Lifted by TrueMark Investments LLC
FY2025 EPS Estimates for AbbVie Lifted by Cantor Fitzgerald
Leerink Partnrs Has Pessimistic View of AbbVie Q3 Earnings
Get AbbVie News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABBV Media Mentions By Week

ABBV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABBV
News Sentiment

1.03

0.50

Average
Medical
News Sentiment

ABBV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABBV Articles
This Week

83

51

ABBV Articles
Average Week

Get the Latest News and Ratings for ABBV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AbbVie and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (NYSE:ABBV) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners